Pulmonary insulin administration using the AERx® insulin diabetes system

Diabetes Technology and Therapeutics

Volumn 4, Issue 4, 2002, Pages 499-504

  Thipphawong, John ^a   Otulana, Babatunde ^a   Clauson, Per ^b   Okikawa, Jerry ^a   Farr, Stephen J ^a  

^a ARADIGM CORPORATION   (United States)

^b NOVO NORDISK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN;

AEROSOL; AREA UNDER THE CURVE; BIOEQUIVALENCE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW;

ADMINISTRATION, INHALATION; AEROSOLS; AREA UNDER CURVE; BLOOD GLUCOSE; DIABETES MELLITUS; FASTING; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN;

EID: 0036381765     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/152091502760306580     Document Type: Review

References (19)

1. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.
2. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes in the development and progression of longterm complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-1036.
3. Gänsslen M: Uber inhalation von insulin. Klin Wochenschrift 1925;2:71-72.
4. Skyler JS, Cefalu WT, Kourides IA, Landschultz WH, Balagtas CC, Cheng S, Gelfand RA: Efficacy of inhaled insulin in type I diabetes mellitus: a randomized proof-of-concept study. Lancet 2001;357:331-335.
5. Farr SJ, McElduff A, Mather LE, Okikawa JE, Ward ME, Gonda I, Licko V, Rubsamen RM: Pulmonary insulin administration using the AERx system: physicochemical and physiological factors influencing insulin effectiveness in healthy fasting subjects. Diabetes Technol Ther 2000;2:185-197.
6. Heise T, Rave K, Bott S, Sha S, Willavize SA, Carroll RS, Gruber S, Lee JD, Heinemann L: Time action profile of an inhaled insulin preparation in comparison to insulin lispro and regular insulin [abstract]. Diabetes 2000;49:A10.
7. Farr S, Reynolds D, Nat A, Srinivasen S, Roach M, Jensen S, Poulsen JU: Technical development of AERx diabetes management system: essential characteristics for diabetes treatment with pulmonary insulin. In: Byron PR, Dalby RN, Peart J, Farr SJ, eds. Respiratory Drug Delivery VIII, Vol. 1. Raleigh: Davis Horwood International, 2002:51-59.
8. Brünner GA, Balent B, Ellmerer M, Schaupp L, Siebenhofer A, Jendle J, Okikawa J, Pieber T: Dose-response relation of liquid aerosol inhaled insulin in type I diabetic patients. Diabetologia 2001;44:305-308.
9. Kipnes M, Otulana B, Okikawa J, Farr S, Jendle J, Thipphawong J, Schwartz S: Pharmacokinetics and pharmacodynamics of pulmonary insulin delivered via the AERx diabetes management system in type 1 diabetics [abstract]. Diabetes 1999;48(Suppl 1):A95.
10. Heise T, Scharling B, Bellaire S, Tusekl C, Bottl S: Dose-response of pulmonary insulin with the AERx insulin diabetes management system in healthy subjects [abstract]. Diabetologia 2001;44(Suppl 1):A212.
11. McElduff A, Clauson P, Mather LE, Okikawa J, Otulana B, Thipphawong J: The pharmacokinetic and pharmacodynamics of a single and divided dose of inhaled insulin via the AERx insulin Diabetes Management System [abstract A34]. Presented at the Diabetes Technology Meeting, November 2001, San Francisco.
12. Köhler D: Aerosols for systemic treatment. Lung 1990;Suppl:677-684.
13. Mellen A, Himmelmann A, Jendle, J, Wollmer P: Pharmacokinetics and intra-subject variability of inhaled insulin in healthy smokers and non-smokers [abstract]. Diabetes 2001;50(Suppl 2):A126.
14. Henry R, Mudaliar S, Howland W, Chul N, Kim D, An B, Reinhardt R: Pulmonary delivery of insulin using the AERx insulin diabetes management system in healthy and asthmatic subjects [abstract]. Diabetologia 2001;44(Suppl 1):A5.
15. McElduff A, Clauson P, Uy C, Kam P, Mather LE: Pulmonary absorption profiles of insulin during and after an upper respiratory tract infection in healthy volunteers using the AERx insulin diabetes management system. An open labeled cross-over study in healthy volunteers. Poster presented at the 62nd Annual Meeting of the American Diabetes Association, 2002, San Francisco.
16. Henry R, Mudaliar S, Chu N, Kim D, Armstrong D, An R, Reinhardt R: Pharmacokinetics and pharmacodynamics of pulmonary insulin in young and elderly type 2 diabetic patients using the AERx insulin diabetes management system. Poster presented at the 62nd Annual Meeting of the American Diabetes Association, 2002, San Francisco.
17. Kapitza C, Hompesch M, Thomsen LK, Heise T: Intra-subject variability of pulmonary insulin via the AERx insulin diabetes management system versus subcutaneous insulin. Poster presented at the 62nd Annual Meeting of the American Diabetes Association, 2002, San Francisco.
18. Okikawa J, Rubin J, Linn L, Farr S, Otulana B, Thipphawong J: Using the AERx iDMS electronic monitoring tools to optimize diabetic patient management [abstract A37]. Presented at the Diabetes Technology Meeting, November 2001, San Francisco.
19. Hermansen K, Ronnemaa T, Petersen AH, Adamson U: Intensive treatment with pulmonary insulin using the AERx insulin diabetes management system - a proof of concept trial in type 2 diabetic patients. Poster presented at 62nd Annual Meeting of the American Diabetes Association, 2002, San Francisco.